tiprankstipranks
Advertisement
Advertisement
Cytokinetics report ‘arguably a best-case scenario’ for Edgewise, says Stifel
PremiumThe FlyCytokinetics report ‘arguably a best-case scenario’ for Edgewise, says Stifel
22d ago
Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James
Premium
The Fly
Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James
22d ago
Edgewise Therapeutics rises 23.3%
Premium
The Fly
Edgewise Therapeutics rises 23.3%
22d ago
Controversial Prasad leaving FDA, NYT reports
PremiumThe FlyControversial Prasad leaving FDA, NYT reports
3M ago
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
Premium
Company Announcements
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
3M ago
Edgewise Therapeutics price target raised to $45 from $30 at Evercore ISI
Premium
The Fly
Edgewise Therapeutics price target raised to $45 from $30 at Evercore ISI
3M ago
Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts
PremiumRatingsEdgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts
5M ago
Edgewise Therapeutics rises 20.3%
Premium
The Fly
Edgewise Therapeutics rises 20.3%
5M ago
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
Premium
Ratings
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100